CFO Brian Stephenson exits Bridgebio

CFO Brian Stephenson is departing Bridgebio Pharma Inc. (NASDAQ:BBIO) for personal reasons. Stephenson will be succeeded by President and COO Thomas Trimarchi, who joined the company as chief product officer in 2018. In December, FDA approved Bridgebio’s Attruby acoramidis for transthyretin amyloid cardiomyopathy.

Edward Kaye is stepping down as CEO of Stoke Therapeutics Inc. (NASDAQ:STOK) after seven years at the RNA medicines company. The company named Ian Smith, a director, as interim CEO, and said Chairman Arthur Tzianabos would become executive chair on an interim basis while it searches for a new CEO. The announcement came with the company’s 4Q24 financial results, in which it said it had $246.7 million in cash as of Dec. 31, 2024. Stoke said the cash, plus the $165 million up front it received from Biogen Inc. (NASDAQ:BIIB) under collaboration announced last month, is expected to fund operations to mid-2028. ...